Personalised SeptiCyte® monitoring of severe sepsis

Athlomics’ SeptiCyte® lab product, a molecular biomarker-based sepsis diagnostic test, is faster (less than three hours) and more accurate (85 to 95% performance) than all competitors.

Athlomics will use a Proof of Concept grant from Commercialisation Australia to evaluate its use in continuous patient monitoring. This could significantly improve market opportunity, patient surveillance and survival, and reduce antibiotic costs and hospital stays.